What one share of Cellyan Biotechnology Co. holds
China. While over 90% of the products we deal with are OTC pharmaceutical products on average, our portfolio also includes non-pharmaceutical items such as health supplements.
Cellyan Biotechnology Co.’s numbers from its SEC filings, divided by its shares. Results cover the latest fiscal year to 2026-03-31; the balance sheet is as of 2026-03-31.
| Sales | $0.82 |
|---|---|
| Profit | −$0.07 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.05 |
| Cash and investments | $0.01 |
| Debt | $0.05 |
| Book value | $0.59 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2026 | $0.82 | −$0.07 | $0.00 | −$0.05 | — | $0.59 |
Common questions about Cellyan Biotechnology Co.
How much does one share of Cellyan Biotechnology Co. earn?
Over its latest fiscal year, Cellyan Biotechnology Co. lost $0.07 for each share on $0.82 of sales.
Does Cellyan Biotechnology Co. pay a dividend?
Cellyan Biotechnology Co. didn’t pay a dividend over its latest fiscal year, according to its SEC filings.
What is Cellyan Biotechnology Co.’s book value per share?
Cellyan Biotechnology Co.’s book value is $0.59 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of March 31, 2026.
How much cash and debt does each share of Cellyan Biotechnology Co. have?
Each share of Cellyan Biotechnology Co. has $0.01 of cash and investments and $0.05 of debt, as of March 31, 2026.
What is Cellyan Biotechnology Co.’s free cash flow per share?
−$0.05 per share over its latest fiscal year. Free cash flow is the cash left over after spending on buildings and equipment.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.